Qiagen N.V. (FRA:QIA)
Market Cap | 8.89B |
Revenue (ttm) | 1.85B |
Net Income (ttm) | 86.67M |
Shares Out | n/a |
EPS (ttm) | 0.39 |
PE Ratio | 102.61 |
Forward PE | 20.06 |
Dividend | 1.21 (2.98%) |
Ex-Dividend Date | Jan 29, 2025 |
Volume | 376 |
Average Volume | 520 |
Open | 40.51 |
Previous Close | 40.54 |
Day's Range | 40.39 - 40.70 |
52-Week Range | 32.50 - 47.53 |
Beta | n/a |
RSI | 63.27 |
Earnings Date | Jul 28, 2025 |
About Qiagen
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and... [Read more]
Financial Performance
In 2024, Qiagen's revenue was $1.98 billion, an increase of 0.66% compared to the previous year's $1.97 billion. Earnings were $83.59 million, a decrease of -75.51%.
Financial numbers in USD Financial StatementsNews

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (A...

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman ...

Qiagen and Gencurix Enter Clinical Diagnostics Partnership
The companies said Wednesday the partnership combines Qiagen's QIAcuityDx platform, a digital polymerase chain reaction system, with Gencurix's expertise in assay development for oncology tests.
Qiagen and Gencurix partner for oncology tests

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a high-performan...

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assa...

Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Shares of Incyte Corporation (NASDAQ: INCY) rose sharply in today's pre-market trading . QIAGEN and Incyte disclosed a precision medicine collaboration to develop companion diagnostics for patients w...

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio...

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration t...
Tracer Biotechnologies and QIAGEN to advance blood-based MRD testing for solid tumors

Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors
NEW YORK--(BUSINESS WIRE)--Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Sta...
QIAGEN expands portfolio for MRD testing in oncology with two partnerships

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its oncology diagnostics portfolio with two strategic partnerships to advance the use of minimal residual disease (M...

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its oncology diagnostics portfolio with two strategic partner...

Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma
BOULDER, Colo. , Jun 2, 2025 /PRNewswire/ -- Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic,...

QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of ...
Qiagen Beats Earnings, But Its Expensive Valuation Caps Upside Potential
QIAGEN acquires AI-powered software, Genoox

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software
VENLO, the Netherlands & TEL AVIV, Israel--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has signed a definitive agreement to acquire Genoox,...
Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript
Qiagen N.V. 2025 Q1 - Results - Earnings Call Presentation

QIAGEN announces plans for transition in leadership of Supervisory Board
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board intends to elect Stephen H. Rusckowski to ...

QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today confirmed strong Q1 2025 results in line with the preliminary announcement and ...
Qiagen declares $0.25 dividend

QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board will propose the initiation of an annual cash dividend under an amended dividend policy to QIAGEN’s s...